Avacopan
- CAS No.
- 112093-28-4
- Chemical Name:
- Avacopan
- Synonyms
- Endoxifen;(Z)-Endoxifen;Avacopan;Endoxifen(Z);Endoxifen (Z-isomer);Tamoxifen Impurity 15;Tamoxifen Citrate Impurity 15;Endoxifen HCl Endoxifen Z-isomer;(Z)-4-Hydroxy-N-desmethyl Tamoxifen;Endoxifen (Z-isomer), 10 mM in DMSO
- CBNumber:
- CB31872472
- Molecular Formula:
- C25H27NO2
- Molecular Weight:
- 373.49
- MDL Number:
- MOL File:
- 112093-28-4.mol
- MSDS File:
- SDS
- TDS File:
- TDS
| Product description | Number | Pack Size | Price |
| Endoxifen Asreported | 255247 | 10mg | $480 |
| Endoxifen Asreported | 255247 | 50mg | $1338 |
| (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)| | 013646 | 1mg | $638 |
| Z-Endoxifen | BE172975 | 0.1g | $908.6 |
| Z-Endoxifen | BE172975 | 0.25g | $1622.5 |
| More product size | |||
| Melting point | 127-129°C |
|---|---|
| Boiling point | 519.3±50.0 °C(Predicted) |
| Density | 1.099±0.06 g/cm3(Predicted) |
| storage temp. | Amber Vial, -86°C Freezer, Under Inert Atmosphere |
| solubility | DMSO : 50 mg/mL (133.87 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| form | Powder |
| pka | 10.36±0.15(Predicted) |
| color | White to off-white |
| Stability | Light Sensitive, Temperature Sensitive |
| InChI | InChI=1S/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24- |
| InChIKey | MHJBZVSGOZTKRH-IZHYLOQSSA-N |
| SMILES | C1(O)=CC=C(/C(/C2=CC=C(OCCNC)C=C2)=C(/C2=CC=CC=C2)\CC)C=C1 |
| FDA UNII | 46AF8680RC |
| UNSPSC Code | 12352200 |
| NACRES | NA.77 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) | ![]() ![]() ![]() GHS07,GHS08,GHS09 |
|---|---|
| Signal word | Danger |
| Hazard statements | H302-H361-H372-H410 |
| Precautionary statements | P201-P264-P280-P301+P330+P331-P312 |
| WGK Germany | WGK 3 |
| Storage Class | 6.1C - Combustible acute toxic Cat.3 toxic compounds or compounds which causing chronic effects |
| Hazard Classifications | Aquatic Acute 1 Aquatic Chronic 1 Carc. 1A Repr. 1B |
Avacopan price More Price(54)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Usbiological | 255247 | Endoxifen Asreported | 112093-28-4 | 10mg | $480 | 2026-06-03 | Buy |
| Usbiological | 255247 | Endoxifen Asreported | 112093-28-4 | 50mg | $1338 | 2026-06-03 | Buy |
| Usbiological | 013646 | (Z)-4-Hydroxy-N-desmethyl Tamoxifen (contains up to 10% E isomer)| | 112093-28-4 | 1mg | $638 | 2026-06-03 | Buy |
| Biosynth | BE172975 | Z-Endoxifen | 112093-28-4 | 0.1g | $908.6 | 2026-06-04 | Buy |
| Biosynth | BE172975 | Z-Endoxifen | 112093-28-4 | 0.25g | $1622.5 | 2026-06-04 | Buy |
Avacopan Chemical Properties,Uses,Production
Chemical Properties
Off-White to Pink Solid
Uses
A novel active metabolite of the anti-cancer drug Tamoxifen. It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast ca
Uses
A novel active metabolite of the anti-cancer drug Tamoxifen (T006000). It showed potent ER binding property, blocked estrogen stimulated growth of breast cancer cell and half maximal inhibition of estrogen responsive gene expression in ER pos. human breast cancer cell line.
Indications
Avacopan is approved for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). These two diseases are the two most common forms of non-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a systemic autoimmune disease.
Definition
ChEBI: 4-Hydroxy-N-desmethyltamoxifen is a stilbenoid.
brand name
Tavneos
Biological Activity
(Z)-Endoxifen (endoxifen) is an active tamoxifen metabolite generated via actions of cytochrome P450 (CYP) enzymes CYP3A4/5 and CYP2D6. Endoxifen is more potent than tamoxifen as a selective estrogen receptor modulator (SERM) both in vitro and in vivo with good pharmacokinetics and oral availability (∼80% MCF-7 tumor growth inhibition with 4-8 mg/kg/day endoxifen or 20 mg/kg/day tamoxifen in mice via p.o.). Endoxifen also exhibits 4-fold higher PKC inhibitory potency than tamoxifen and can overcome tamoxifen resistance due to cytochrome CYP2D6 polymorphism.
Synthesis
The synthetic route for Avacopan is shown below: first, ethyl 3-(4-nitrophenyl)-3-oxopropanoate 18.1 was reacted with acrolein diethyl acetal in the presence of (R)-(-)-2-phenylglycidinol 18.2 to give tetrahydropyridine 18.3. Next, stereoselective olefinic reduction was carried out by palladium-catalysed hydrogenation ( possibly due to the stereoisomerism introduced by 18.2), along with nitro reduction and removal of the bis-epoxazole fragment to form piperidine. The crude amino ester was obtained as 78% ee by reductive amination with cyclopentanone. Subsequently, the 1:2 amine:salt adduct 18.4 was obtained in 70% yield from 18.3 by forming a salt with (-)-O,O′-di-p-tolyl-L-tartaric acid with an ee value >99:1. Saltolysis and an acylation reaction with 2-fluoro-6-methylbenzoyl chloride 18.5 yielded the amide 18.6. Finally, the amide 18.6 was formed via a Lewis acid-mediated amidation reaction with 4-methyl-5-trifluoromethylaniline 18.7, Avacopan (18) was obtained in 80% yield with de and ee >99.8%.
in vivo
Z-Endoxifen (Z-isomer) (5 mg/kg/day, s.c., gradual drug release every 30 days, pellets replaced every 90 days) effectively prevents breast cancer in the C3(1)-TAg mouse model[3]. Z-Endoxifen (50 mg/kg, p.o., 5 times a week for 4 weeks) shows better antitumor efficacy in the MCF7LR resistant mouse model[4]. Z-Endoxifen (75 mg/kg, p.o., once daily for 4 weeks) shows strong antitumor activity in the MCF7AC1 mouse breast cancer model[4].
| Animal Model: | C3(1)-TAg mouse mammary tumorigenesis model, developed by breeding FVB/NJ females with FVB/C3(1)-TAg males (8 weeks), resulting in SV40 T-antigen expression in mammary gland cells and tamoxifen resistance[3] |
| Dosage: | 5 mg/kg/day |
| Administration: | Subcutaneously implanted pellets, replaced every 90 days, with each pellet designed to release the drug gradually over 30 days. |
| Result: | Significantly increased tumor latency and reduced tumor growth. |
| Animal Model: | MCF7LR mouse breast cancer model, simulating endocrine-resistant breast cancer, developed by prolonged exposure to Letrozole[4] |
| Dosage: | Z-Endoxifen: 50 mg/kg (Tamoxifen (HY-13757A): 500 μg/day, Exemestane (HY-13632): 250 μg/day,Everolimus (HY-10218): 2.5 mg/day) |
| Administration: | Z-Endoxifen: oral gavage (p.o.), the others administered subcutaneously, 5 times a week for 4 weeks |
| Result: | Significantly reduced tumor volume in the MCF7LR resistant model compared to Tamoxifen and Exemestane. |
Avacopan Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Jiangxi Huihe Chemical Co., Ltd. | +86-19189228086 +8618858568638 | wuzhouding@huihecrop.com | China | 886 | 58 |
| Shaanxi Dideu Medichem Co. Ltd | +8617392709771 | 1097@dideu.com | China | 3992 | 58 |
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 | ivan@atkchemical.com | China | 33024 | 60 |
| career henan chemical co | +86-0371-86658258 +8613203830695 | sales@coreychem.com | China | 29815 | 58 |
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19936 | 58 |
| Tianjin Xinshengjiahe Science & Technology Development Co,.Ltd | +86-86-22-87899925 +86-8618522618860 | 18522618860@163.com | China | 694 | 58 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 | sales@hzclap.com | CHINA | 6312 | 58 |
| ANHUI WITOP BIOTECH CO., LTD | +8615255079626 | eric@witopchemical.com | China | 23541 | 58 |
| Finetech Industry Limited | +86-27-8746-5837 +8619945049750 | info@finetechnology-ind.com | China | 9539 | 58 |
View Lastest Price from Avacopan manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
![]() |
2026-05-11 | Endoxifen (Z-isomer)
112093-28-4
|
$30.00-85.00 | 99.19% | 10g | TargetMol Chemicals Inc. | ||
![]() |
2025-12-24 | Endoxifen
112093-28-4
|
1KG | 99.0% | 1000KG | Shaanxi Dideu Medichem Co. Ltd | ||
![]() |
2025-11-24 | Avacopan
112093-28-4
|
1KG | 98 | 10000KGS | Shaanxi Dideu New Materials Co. Ltd |
-

- Endoxifen (Z-isomer)
112093-28-4
- $30.00-85.00
- 99.19%
- TargetMol Chemicals Inc.
-

- Endoxifen
112093-28-4
- 99.0%
- Shaanxi Dideu Medichem Co. Ltd
-

- Avacopan
112093-28-4
- 98
- Shaanxi Dideu New Materials Co. Ltd
112093-28-4(Avacopan)Related Search:
1of4







